M Michael

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. pmc Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer
    F L Day
    Department of Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Melbourne, Victoria 8006, Australia
    Br J Cancer 104:265-71. 2011
  2. doi request reprint A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer
    M Michael
    Division of Cancer Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Cancer Chemother Pharmacol 71:321-30. 2013
  3. pmc A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer
    M Michael
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Oncol Rep 28:763-7. 2012
  4. ncbi request reprint Phase II study of activated charcoal to prevent irinotecan-induced diarrhea
    Michael Michael
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Ontario, Canada
    J Clin Oncol 22:4410-7. 2004
  5. ncbi request reprint Tumoral drug metabolism: overview and its implications for cancer therapy
    M Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    J Clin Oncol 23:205-29. 2005
  6. ncbi request reprint Drug metabolism by tumours: its nature, relevance and therapeutic implications
    Michael Michael
    Peter MacCallum Cancer Centre, Division of Haematology and Medical Oncology, Locked Bag 1, A Beckett Street, Victoria, 8006, Australia
    Expert Opin Drug Metab Toxicol 3:783-803. 2007
  7. ncbi request reprint Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count
    Michael Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria, 8006, Australia
    Clin Colorectal Cancer 6:297-304. 2006
  8. pmc A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC
    M Michael
    The Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Br J Cancer 93:652-61. 2005
  9. pmc A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer
    M Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, Victoria 8006, Australia
    Br J Cancer 100:37-43. 2009
  10. doi request reprint Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
    Michael Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, 3002, Australia
    Invest New Drugs 27:253-61. 2009

Detail Information

Publications55

  1. pmc Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer
    F L Day
    Department of Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Melbourne, Victoria 8006, Australia
    Br J Cancer 104:265-71. 2011
    ..The aim of this phase I trial was to assess the maximum tolerated dose (MTD) of a novel weekly docetaxel and cisplatin regimen concurrent with radical radiotherapy...
  2. doi request reprint A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer
    M Michael
    Division of Cancer Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Cancer Chemother Pharmacol 71:321-30. 2013
    ..This phase I study aimed to assess the maximal tolerated dose (MTD) of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer and to identify pharmacokinetic (PK) interactions and toxicities...
  3. pmc A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer
    M Michael
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Oncol Rep 28:763-7. 2012
    ..Erlotinib plus gemcitabine for the treatment of ECOG 2 NSCLC patients warrants further investigation including intermittent erlotinib regimens...
  4. ncbi request reprint Phase II study of activated charcoal to prevent irinotecan-induced diarrhea
    Michael Michael
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Ontario, Canada
    J Clin Oncol 22:4410-7. 2004
    ..The aim of this study was to assess whether activated charcoal (AC), possibly by adsorbing free lumenal SN38, can reduce irinotecan-induced diarrhea (CID) and optimize its dose-intensity...
  5. ncbi request reprint Tumoral drug metabolism: overview and its implications for cancer therapy
    M Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    J Clin Oncol 23:205-29. 2005
    ..Only then can efforts be concentrated in the design of better prodrugs or combination therapy to improve drug efficacy and individualize therapy...
  6. ncbi request reprint Drug metabolism by tumours: its nature, relevance and therapeutic implications
    Michael Michael
    Peter MacCallum Cancer Centre, Division of Haematology and Medical Oncology, Locked Bag 1, A Beckett Street, Victoria, 8006, Australia
    Expert Opin Drug Metab Toxicol 3:783-803. 2007
    ..Only then can efforts be concentrated in the design of better prodrugs or combination therapy to optimise individual therapy...
  7. ncbi request reprint Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count
    Michael Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria, 8006, Australia
    Clin Colorectal Cancer 6:297-304. 2006
    ..The aim of this study was to identify prognostic indicators of survival and response in a homogeneous population of chemotherapy-naive patients treated with oxaliplatin as part of 3 successive trials...
  8. pmc A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC
    M Michael
    The Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Br J Cancer 93:652-61. 2005
    ..This regimen was tolerable and produced meaningful responses for patients for whom locoregional control is required, but who are unsuitable for radical CRT...
  9. pmc A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer
    M Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, Victoria 8006, Australia
    Br J Cancer 100:37-43. 2009
    ..Dose level 2 was the recommend phase 2 dose. Disease control rate was 75%: PR=15%, SD=60%. Median overall survival was 11.2 months. The addition of Cap and Gem to radical RT was feasible and active and achieved at relatively low doses...
  10. doi request reprint Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
    Michael Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, 3002, Australia
    Invest New Drugs 27:253-61. 2009
    ..The safety and tolerability of vandetanib plus mFOLFOX6 was investigated in patients with advanced colorectal cancer (CRC)...
  11. ncbi request reprint Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination
    Michael Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia
    J Clin Oncol 24:4228-35. 2006
    ....
  12. pmc Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor
    M Michael
    Peter MacCallum Cancer Centre, Consultant Medical Oncologist, Division of Haematology and Medical Oncology, Chair of GI Clinical Service, Locked Bag 1, A Beckett Street, Victoria 8006, Australia
    Br J Cancer 103:1554-61. 2010
    ..Tumoural interstitial hypertension, possibly modulated by platelet-derived and vascular endothelial growth factor receptors (PDGFR and VEGFR), may mediate resistance to chemotherapy...
  13. doi request reprint Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test
    M Michael
    Division of Cancer Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Melbourne, VIC 8006, Australia
    Cancer Chemother Pharmacol 69:125-35. 2012
    ..This is the first report directly comparing the erythromycin breath test (EBT) (a CYP3A4 probe) with the antipyrine clearance test (ACT), (a general CYP-P450/predominant CYP3A4 probe) for the correlation with docetaxel PK and toxicity...
  14. pmc Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial
    S Loi
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, A Beckett Street, Melbourne, Victoria 8006, Australia
    Br J Cancer 92:655-61. 2005
    ..For future trials, oxaliplatin 85 mg m(-2) and 5-FU 200 mg m(-2) day(-1) continuous infusion 96 h week(-1) is the recommended dose when combined with 50.4 Gy of pelvic radiotherapy...
  15. pmc Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients
    D Goldstein
    Department of Medical Oncology, Prince of Wales Hospital, Randwick, Sydney, NSW 2031, Australia
    Br J Cancer 92:832-7. 2005
    ..Median progression-free survival was 8.2 months (7.1-9.9) and median overall survival was 18.7 months (14.0-23.4). In our experience, a modified schedule of FOLFOX improves convenience without compromising efficacy or toxicity...
  16. ncbi request reprint Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer
    B Solomon
    Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, VIC 3002, Australia
    Lung Cancer 41:353-61. 2003
    ..Paclitaxel can be safely given twice-weekly at a dose of 30 mg/m(2) in combination with weekly cisplatin (20 mg/m(2)) and thoracic RT (60 Gy), and this regimen has significant activity in stage III NSCLC...
  17. ncbi request reprint A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer
    S J Dawson
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria, 8006, Australia
    Invest New Drugs 25:123-9. 2007
    ..The study's aim was to determine the maximum tolerated dose (MTD) of celecoxib combined with chemoradiotherapy (CRT) for locally advanced oesophageal cancer (OC)...
  18. pmc Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation
    T Leong
    Peter MacCallum Cancer Centre, St Andrews Place, Melbourne, Victoria 3002, Australia
    Br J Cancer 89:1433-8. 2003
    ..Our results suggest that this adjuvant regimen can be delivered safely and with acceptable toxicity. This regimen forms the basis of several new studies being developed for postoperative adjuvant therapy of gastric cancer...
  19. pmc Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer
    D Goldstein
    Department of Medical Oncology, Prince of Wales Hospital, Barker Street, Randwick, New South Wales 2031, Australia
    Br J Cancer 97:464-71. 2007
    ..This approach to treatment of locally advanced pancreatic cancer is safe and promising, with good local control for a substantial proportion of patients, and merits testing in a randomised trial...
  20. pmc Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
    W Chua
    Department of Medical Oncology, Sydney Cancer Centre, Concord Repatriation General Hospital, Sydney, NSW, Australia
    Br J Cancer 101:998-1004. 2009
    ....
  21. pmc FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy
    F L Day
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, 8006, Victoria, Australia
    Br J Cancer 105:498-504. 2011
    ..The aim was to investigate the correlation between (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) metabolic response to chemoradiotherapy and clinical outcomes in squamous cell carcinoma (SCC) of the anus...
  22. pmc A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer
    S Y K Ngan
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Br J Cancer 91:1019-24. 2004
    ..4 Gy. For patients with resectable rectal cancer receiving concurrent, full dose radiotherapy, the recommended dose of capecitabine for further study is 1800 mg m(-2) day(-1) when given in this schedule...
  23. ncbi request reprint A phase I trial of docetaxel and gemcitabine in patients with advanced cancer
    D Rischin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Ann Oncol 11:421-6. 2000
    ..Docetaxel and gemcitabine are active in a broad range of malignancies. The objective of this phase I trial was to determine the maximally tolerated doses of the combination of docetaxel and gemcitabine...
  24. pmc Gastrointestinal stromal tumour treated with neoadjuvant imatinib
    M B Loughrey
    Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3002, Australia
    J Clin Pathol 58:779-81. 2005
    ..The implications for this management option of radiological, pathological, and molecular assessment are discussed...
  25. doi request reprint Metabolic response of rectal cancer assessed by 18-FDG PET following chemoradiotherapy is prognostic for patient outcome
    J M C Yeung
    Department of Surgical Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, Australia
    Dis Colon Rectum 54:518-25. 2011
    ..Sequential 18-FDG PET may be an early surrogate for pathological response to chemoradiotherapy...
  26. ncbi request reprint The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial
    M Michael
    Department of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Locked Bag 1, A Beckett St, Victoria, 8006, Australia
    Clin Colorectal Cancer 2:93-101. 2002
    ..2 months. Irinotecan provides a rate of palliative benefit higher than the radiological response rate. Patients-oriented palliative endpoints can be useful in assessing the benefit of agents in early-phase clinical trials...
  27. ncbi request reprint Tumoral drug metabolism: perspectives and therapeutic implications
    M M Doherty
    Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, 3052, Victoria, Australia
    Curr Drug Metab 4:131-49. 2003
    ..Various gene therapy approaches have been attempted experimentally with promising results. However, there are major gaps in understanding the implications of tumoral DME in disease progression (including metastasized tissue) and relapse...
  28. ncbi request reprint Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors
    A Patnaik
    Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Canada
    J Clin Oncol 18:3677-89. 2000
    ....
  29. ncbi request reprint Association of acquired Pelger-Huet anomaly with taxoid therapy
    S K Juneja
    Department of Pathology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Br J Haematol 93:139-41. 1996
    ..001) and for paclitaxel compared with controls (P = 0.007). We conclude that taxoid therapy produces transient APHA which peaks between days 3 and 9 and is more pronounced with docetaxel than with paclitaxel...
  30. doi request reprint Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Grou
    Trevor Leong
    Division of Radiation Oncology, Department of Radiation Therapy Services, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 79:690-5. 2011
    ..We conducted a prospective, multicenter study to evaluate an alternative chemoradiation regimen that combines more current systemic treatment with modern techniques of radiotherapy delivery...
  31. ncbi request reprint Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer
    Kenneth Khamly
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria 8006, Australia
    Expert Opin Investig Drugs 14:607-28. 2005
    ..This paper reviews these and other advances in the care of patients with advanced colorectal cancer and discusses a number of agents that are currently under development...
  32. ncbi request reprint A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer
    Michael Jefford
    Centre for Developmental Cancer Therapeutics, Melbourne, Victoria, Australia
    Invest New Drugs 22:185-92. 2004
    ..We conducted a dose escalation study combining cisplatin, irinotecan, and capecitabine (CIC), aiming to establish the maximum tolerated doses (MTD), side effect profile, and dose-limiting toxicity (DLT) of this novel regimen...
  33. ncbi request reprint Implications of dose rounding of chemotherapy to the nearest vial size
    Michael Joseph Dooley
    Pharmacy Department, Peter MacCallum Cancer Centre, St Andrew s Place, 3002 East Melbourne, Australia
    Support Care Cancer 12:653-6. 2004
    ..The objective here was to explore the magnitude of the effect of dose rounding to the nearest whole vial strength for some newly marketed expensive cytotoxic chemotherapy agents...
  34. doi request reprint A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients
    Peter Gibbs
    Department of Medical Oncology and Haematology, Royal Melbourne Hospital, Melbourne, Australia
    Chemotherapy 55:49-59. 2009
    ..This study was designed as a first-in-man investigation of the safety and pharmacokinetics of irinotecan when administered within the HA-Irinotecan formulation...
  35. doi request reprint Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme
    J D Mellor
    Pharmacy Department, Monash University, Melbourne, Victoria, Australia
    Intern Med J 42:1224-9. 2012
    ..Our study aimed to document the disparity between evidence-based clinical guidelines for anticancer therapy, product approval and funding status of these agents within an academic tertiary/quaternary cancer centre...
  36. ncbi request reprint A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy
    Sherene Loi
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer Chemother Pharmacol 54:407-14. 2004
    ..We sought to determine the effect of a 3-h infusion of 20 ml/m2 (equivalent to 175 mg/m2 paclitaxel) CrEL on myelosuppression following carboplatin chemotherapy, and the effect of CrEL on carboplatin pharmacokinetics...
  37. ncbi request reprint Long-term survival following chemoradiation for inoperable non-small cell lung cancer
    Nikki M Plumridge
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Med J Aust 189:557-9. 2008
    ..To measure long-term survival following combined chemotherapy and radiotherapy for inoperable non-small cell lung cancer...
  38. doi request reprint 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
    Daniel Hubble
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew s Place, East Melbourne, VIC 3002, Australia
    Eur J Nucl Med Mol Imaging 37:1869-75. 2010
    ....
  39. doi request reprint Part I: Liver function in oncology: biochemistry and beyond
    Kathryn M Field
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, Vic, Australia
    Lancet Oncol 9:1092-101. 2008
    ....
  40. ncbi request reprint Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome
    Ross R Jennens
    Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Urol Oncol 22:193-6. 2004
    ..While vascular endothelial growth factor (VEGF) inhibitors have been shown to produce a modest response in sporadic metastatic RCC, further studies utilizing VEGF inhibitors in patients with VHL syndrome and RCC warrants exploration...
  41. doi request reprint Part II: Liver function in oncology: towards safer chemotherapy use
    Kathryn M Field
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Lancet Oncol 9:1181-90. 2008
    ..Furthermore, we review other assessments of liver metabolic and excretory function, particularly in the setting of chemotherapy drug handling. We discuss the potential use of these metabolic probes in practice...
  42. doi request reprint Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer
    Marie Pierre Campeau
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 74:1371-5. 2009
    ..The effect of CRT on local control in Stage I NSCLC is less well documented. We retrospectively reviewed local control and survival following CRT or RT for inoperable Stage I NSCLC patients...
  43. ncbi request reprint Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience
    Robert Blum
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, East Melbourne, Vic, Australia
    Am J Clin Oncol 27:164-71. 2004
    ..PET-CR conferred longer median time to progression (13.7 months) than no CR (9.7 months). FDG-PET for SCLC was often discordant with conventional assessment and frequently influenced management...
  44. doi request reprint The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum
    Jennifer A Westwood
    Cancer Immunology Research Program, Peter MacCallum Cancer Centre, St Andrews Place, Melbourne, Victoria 3002, Australia
    J Immunother 32:292-301. 2009
    ....
  45. ncbi request reprint FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer
    Cuong P Duong
    Division of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Eur J Nucl Med Mol Imaging 33:770-8. 2006
    ..The purpose of this study was to evaluate the impact of FDG-PET following chemoradiotherapy (CRT) on treatment planning and survival in patients with oesophageal cancer (OC)...
  46. ncbi request reprint Adjuvant therapy in gastric cancer
    Lionel Lim
    Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    J Clin Oncol 23:6220-32. 2005
    ..Issues such as the identification of patients who are more likely to benefit from adjuvant therapy are also addressed. Further clinical trials are needed to move towards better consensus and standardization of care...
  47. doi request reprint Role of xenobiotic metabolic enzymes in cancer epidemiology
    Madhu S Singh
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia
    Methods Mol Biol 472:243-64. 2009
    ..The data may have relevance in one population but not for another for a specific malignancy and at times may be conflicting. We believe that with mature data in the future it may be possible to stratify patients by risk...
  48. ncbi request reprint Recent developments in the systemic therapy of advanced gastroesophageal malignancies
    Kenneth Khamly
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria 8006, Australia
    Expert Opin Investig Drugs 15:131-53. 2006
    ..This article reviews the current clinical data regarding systemic therapy for patients with advanced upper gastrointestinal malignancies...
  49. ncbi request reprint Locally advanced and metastatic gastric cancer: current management and new treatment developments
    Kathryn Field
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Drugs 68:299-317. 2008
    ..Overall, there remains optimism that further incremental gains will be achieved with future studies combining chemotherapy, radiotherapy and targeted therapies, both in the adjuvant and metastatic disease settings...
  50. ncbi request reprint FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burden
    Michael R MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Acta Oncol 42:48-54. 2003
    ..027) but not pre-PET stage, weight loss or metastasis site correlated with survival. PET-detected metastatic tumor burden appeared to influence survival and should be evaluated as a prognostic factor in NSCLC...
  51. ncbi request reprint Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy
    Stephen Clarke
    Department of Medical Oncology, Royal Prince Alfred Hospital Sydney Cancer Centre, Sydney, Australia
    Clin Colorectal Cancer 6:578-82. 2007
    ..This analysis assesses the efficacy and safety of a modified FOLFOX (oxaliplatin/leucovorin [LV]/5-fluorouracil [5-FU]) regimen given with a low dose of LV...
  52. ncbi request reprint Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity
    Paul L Mitchell
    Austin Hospital, Heidelberg, Melbourne, Australia E mail
    Clin Colorectal Cancer 6:146-51. 2006
    ..Sensory neurotoxicity is dose limiting for oxaliplatin, an effective drug in the treatment of colorectal cancer (CRC) and other malignancies. This study assessed the impact of gabapentin on oxaliplatin dose intensity and neurotoxicity...
  53. ncbi request reprint Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: review of a single institution's experience
    Michael Ng
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Thorac Oncol 2:506-13. 2007
    ..We have reviewed the experience at Peter MacCallum Cancer Centre to determine the tolerability of these treatments in routine practice and to determine their effects on survival...
  54. ncbi request reprint Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer
    Fiona H Blackhall
    Department of Medical Oncology, University Health Network Princess Margaret Hospital, University of Toronto, Toronto, Ontario, M5G 2M5 Canada
    Clin Cancer Res 9:2241-7. 2003
    ..This study was designed to examine the expression and importance of Kit, PKB/Akt, and MAPK relative to standard clinical prognostic factors in SCLC...
  55. ncbi request reprint A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy
    Ian D Davis
    Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
    Clin Cancer Res 11:1890-8. 2005
    ....